Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term progression. Found 54 abstracts

no pagination
Bergman A, Gligorijevic B. Niche construction game cancer cells play. Eur Phys J Plus. 2015 Oct;130(10).   PMCID: PMC5027994
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biology & Therapy. 2014 Mar;15(3):329-41.   PMCID: PMC3974843
Cheng F, Wang HW, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao JG, Sotomayor EM. Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity. Cancer Research. 2012 Sep;72(17):4440-8.   PMCID: No Longer Here
Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ. A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E-2 in Patients With Barrett's Esophagus. Gastroenterology. 2012 Oct;143(4):917-U91.   PMCID: PMC3458136
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics. 2012 Nov;11(11):2526-34.   PMCID: PMC 3500676
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology. 2012 May;23(5):1144-50.   PMCID: *
Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Apr;17(2):96-104.   PMCID: *
Mego M, Mani SA, Lee BN, Li CP, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. International journal of cancer. 2012 Feb;130(4):808-16.   PMCID: PMC169728
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 2012 Mar;124(3):563-8.   PMCID: PMC3278517
Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG. Small renal masses progressing to metastases under active surveillance. Cancer. 2012 Feb;118(4):997-1006.   PMCID: NIHMS364390
Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012 Apr;19(4):1074-80.
Zaorsky NG, Li TY, Devarajan K, Horwitz EM, Buyyounouski MK. Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. Cancer. 2012 Nov;118(22):5535-43.   PMCID: PMC3410044
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research. 2011 Jun;13(3):R67.   PMCID: PMC3218956
Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Agliano AM, Gazzaniga P. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology. 2011 Jan;22(1):86-92.   PMCID: not NIH funded
Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. International Journal of Clinical Oncology. 2011 Oct;16(5):596-600.   PMCID: *
Makhov PB, Golovine KV, Kutikov A, Canter DJ, Rybko VA, Roshchin DA, Matveev VB, Uzzo RG, Kolenko VM. Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis. 2011 Dec;32(12):1773-81.   PMCID: PMC3220607
Pimkina JS, Murphy ME. Interaction of the ARF tumor suppressor with cytosolic HSP70 contributes to its autophagy function. Cancer Biology & Therapy. 2011 Sep;12(6):503-9.   PMCID: PMC3218591
Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: A tool whose time has come of age. BMC Medicine. 2011 Apr;9:43.   PMCID: PMC3107794
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term progression

progression survival chemotherapy expression metastasis peripheral-blood resistance circulating tumor cells breast cancer gene amplification stem-cells system circulating tumor-cells therapy carcinoma phenotype tumors breast-cancer trial markers follow-up marker solid tumors guidelines disease her2 RCC GENE-EXPRESSION grade thymidine kinase 1 activation independent prognostic-factor natural-history rising incidence cell RCC in-vivo methylation ANGIOGENESIS KIDNEY CANCER conservative management mutations PATHWAYS platinum-resistant phase-ii Circulating tumor cell clear growth risk HSP70 STEM-CELLS prognosis radical nephrectomy DIFFERENTIATION tumor size target tumorigenesis randomized-trial tumor-suppressor gene HER2 circulating tumor cells-immunohistochemical subtypes-metastatic breast cancer-tumor markers cytotoxic t-lymphocytes cancer active surveillance Breast neoplasm Circulating tumor cell-HER2-Metastasis profile ca125 response criteria acid mdm2 p19(arf) staging prostate cancer-radiotherapy-American Joint Committee on Cancer-National Comprehensive Cancer Network aneusomy ap-2-alpha neoadjuvant therapy Oncology adenocarcinoma down-regulation dendritic cells drug gleason score delayed TISSUE estrogen-receptor stage-i Ovarian cancer egf blood ursodeoxycholic RNA mitochondria chronic kidney-disease 1975 cock sj-biometrics-v31-p103 slug positron-emission-tomography AKT inhibitor neoplasms colorectal carcinoma carcinomas mammalian target Polysomy cell lung-cancer therapeutic target partial primary ovarian transcription factor ap-2 cell-proliferation men solid predictive-value p53 ca 125 Breast neoplasm epithelial-mesenchymal transition induction chemotherapy CARCINOMA psa velocity Bevacizumab evolution half-life conformal radiation-therapy consensus refractory radical prostatectomy ca-15-3 small-molecule inhibitor IDENTIFICATION prognostic-factors Ovarian clinical trial resistant prostate-cancer PI3K pathway Response assessment bevacizumab hzip1 resection antigen-presenting cells bone-marrow Circulating tumor cells cross-presentation tumor-cells mTOR nephrectomy cyclooxygenase-2 gist intervention diagnosis 2010 orgoulias v-j clin oncol-v28-ps15 HER2 carcinoma patients tumor marker kit
Last updated on Sunday, July 05, 2020